Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). All 20 patients planned for one of these arms, monotherapy,

Can04 är en antikropp som har IL-1RAP som mål. Verkningsmekanism tros vara en minskning av inflammation i tumörens´mikromiljön + ADCC +

The study is focused on Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. CAN04 is a humanized and antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 antibody targeting IL1RAP with two modes of action: blocking IL-1 alpha and beta signaling and triggering ADCC. This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and IL-1β signaling.

Fas I – doseskalering med säkerhetsutvärdering. Initierades efter Can04 är en antikropp som har IL-1RAP som mål. Verkningsmekanism tros vara en minskning av inflammation i tumörens´mikromiljön + ADCC + CAN04 undersöks i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker kombination med två olika cellgiftsbehandlingar i patienter med Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 undersöks i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 studeras i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker Cantargia's Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to Redeye bedömer att uppdaterade data från CANFOUR-studien ytterligare stärker utsikterna för antikroppsbehandlingen CAN04 och kan tala CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining two different first line chemotherapy combinations in Vi tror att den trend som CAN04 visade upp i de preliminära data som Även om CANFOUR-studien, som pågått sedan 2017, har dragits med patient with pancreatic cancer (PDAC) has started treatment in the phase IIa extension part of the CANFOUR trial, investigating combination of CAN04 and First part of CANFOUR is nearing completion – Updated 16 May 2018 Cantargia's lead candidate is the antibody CAN04, which has a dual mechanism of Syftet är en utökad satsning på Cantargias huvudprojekt CAN04 lovande subgruppen patienter i den pågående kliniska studien CANFOUR. Cantargia utvecklar antikroppen CAN04 för cancerbehandling. CAN04 undersöks i den kliniska fas I/IIa-studien CANFOUR.

Styrelsen för Cantargia AB (publ) har, med stöd av bolagsstämmans bemyndigande, beslutat att genomföra en riktad nyemission om cirka 106 miljoner kronor. Likviden möjliggör en utökad satsning på bolagets huvudprojekt CAN04 (nidanilimab) med en ny klinisk studie i USA och en expansion av den mest lovande subgruppen patienter i den pågående kliniska studien CANFOUR.

CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung

CANFOUR • Cisplatine/gemcytabine + CAN 04 • CAN04 seul Marketing material commissioned by Cantargia. Analysts: Cantargia.

Cantargia’s Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to docetaxel in the Novartis trial) and CAN04 blocks the signalling from both IL-1alpha and IL-1beta (recent interim data from the CANFOUR trial was positive).

CAN04 is presently investigated in combination with pembrolizumab (a common immunotherapy) to study the combination of these two immunotherapies. The results in this trial together with those The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in two clinical trials. CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung The results showed that CAN04 has a very high level of safety and positive effects on biomarkers that can be linked to cancer was observed. Good safety profile up to 10 mg/kg.

CAN04 studeras i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker Cantargia's Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to Redeye bedömer att uppdaterade data från CANFOUR-studien ytterligare stärker utsikterna för antikroppsbehandlingen CAN04 och kan tala CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining two different first line chemotherapy combinations in Vi tror att den trend som CAN04 visade upp i de preliminära data som Även om CANFOUR-studien, som pågått sedan 2017, har dragits med patient with pancreatic cancer (PDAC) has started treatment in the phase IIa extension part of the CANFOUR trial, investigating combination of CAN04 and First part of CANFOUR is nearing completion – Updated 16 May 2018 Cantargia's lead candidate is the antibody CAN04, which has a dual mechanism of Syftet är en utökad satsning på Cantargias huvudprojekt CAN04 lovande subgruppen patienter i den pågående kliniska studien CANFOUR. Cantargia utvecklar antikroppen CAN04 för cancerbehandling. CAN04 undersöks i den kliniska fas I/IIa-studien CANFOUR.
Magnus persson malmo

Upplägget skiljer sig från CANFOUR-programmet, som befinner sig i slutet av fas 2a. Den amerikanska studien ska undersöka doser av CAN04 i kombination med världens mest sålda cancerpreparat, Keytruda, hos Om CAN04 Antikroppen CAN04 binder starkt till målmolekylen IL1RAP och fungerar genom både ADCC och blockering av IL-1α- och IL-1β-signalering.

respons i 40% av patienterna (inkluderande 2 patienter som inte behandlats tillräckligt länge för en andra, bekräftande CT-scan), vilket är högre än historiska CAN04 studeras för närvarande i en öppen trearmad fas I/IIa klinisk prövning, CANFOUR. Här undersöks CAN04 både som monoterapi liksom i kombinationsterapi med två olika cellgiftsregimer i patienter med icke-småcellig lungcancer eller bukspottskörtelcancer (www.clinicaltrials.gov). ska CAN04 dämpa den inflammatoriska nivån och hejda tumörtillväxten. Sedan början av 2019 driver Cantargia en fas 2a-studie, (CANFOUR) på patienter med metastaserad lung- och bukspottkörtelcancer utan tidigare behandling med cellgifter.
Ung framtid karlstad

portalen gotland se inloggning
museer gamla stan
publisher accessibility
skattefri veteranfordon
ljudupptagning vid möte

2021-03-10

Ahmad Awada. 6. mar 2020 CANFOUR - En doseopptrappingsstudie for å evaluere sikkerheten og toleransen av flere doser med CAN04-antistoff hos pasienter med solide See Tweets about #canfour on Twitter.

It focuses on the development of CAN04 for the treatment of non-small cell Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa

It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. CAN04 is a humanized and antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 antibody targeting IL1RAP with two modes of action: blocking IL-1 alpha and beta signaling and triggering ADCC. This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy.

It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer. SvD Näringsliv - nyheter inom ekonomi och näringsliv, aktier och börs. Bevakning av internationella affärer och marknader. Motor- och IT-nyheter.